（於開曼群島註冊成立的有限公司） 股份代號：2197 目錄表 | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 6 | 業務摘要 | | 7 | 管理層討論與分析 | | 19 | 其他資料 | | 42 | 中期簡明綜合損益表 | | 43 | 中期簡明綜合全面收益表 | | 44 | 中期簡明綜合財務狀況表 | | 46 | 中期簡明綜合權益變動表 | | 48 | 中期簡明綜合現金流量表 | | 50 | 中期簡明綜合財務資料附註 | | 77 | 釋義 | 公司資料 董事會 執行董事 梁朋博士 （董事長） 梁果先生 2025中期 報告 Clover Biopharmaceuticals, Ltd. 三 葉 草 生 物 製 藥 有 限 公 司 非執行董事 王曉東博士 Donna Marie AMBROSINO博士 Ralf Leo CLEMENS博士 （於2025年6月19日退任） 獨立非執行董事 吳曉濱博士 廖想先生 Jeffrey FARROW先生 Thomas LEGGETT先生 審核委員會 Thomas LEGGETT先生 （主席） 廖想先生 Jeffrey F ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 三葉草生物製藥有限公司 (「本公司」) (於開曼群島註冊成立的有限公司) 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02197 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.0001 | USD | | 200,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.0001 ...

Group 1 - Pharmaceutical stocks continue to rise, with notable increases in companies such as BeiGene (up 7.87%), Clover Biopharma (up 6.03%), and Tigermed (up 5.03%) [1] - BlackRock increased its stake in 3SBio by acquiring approximately 47.6 million shares at a price of HKD 30.1096 per share, totaling around HKD 14.33 billion, raising its ownership to 5.1% [1] - The overall performance of Hong Kong pharmaceutical companies in the first half of the year has been robust, with companies like Hengrui Medicine and Hansoh Pharmaceutical reporting record high revenues and profits [1] Group 2 - The pharmaceutical sector has shown strong stock performance in the first half of the year, driven by continuous business development (BD) overseas, excellent clinical data, and supportive policies [2] - The innovative drug sector is experiencing rapid sales growth, with several key products being approved and included in medical insurance, leading to increased domestic sales [2] - Companies like BeiGene and Hutchison China MediTech have successfully commercialized their products overseas, contributing significantly to revenue growth [2]

Group 1 - Pharmaceutical stocks continued to rise, with notable increases in companies such as BeiGene (up 7.87% to HKD 209.8), Clover Biopharmaceuticals (up 6.03% to HKD 1.23), and Tigermed (up 5.03% to HKD 50.5) [1] - BlackRock increased its stake in 3SBio by acquiring approximately 47.6 million shares at a price of HKD 30.1096 per share, totaling around HKD 14.33 billion, raising its ownership to about 124 million shares or 5.1% [1] - The overall performance of Hong Kong pharmaceutical companies was robust in the first half of the year, with companies like Heng Rui Medicine achieving record revenue and profit, and Hansoh Pharmaceutical exceeding revenue expectations [1] Group 2 - The pharmaceutical sector performed well in the first half of the year, driven by continuous business development overseas, strong clinical data, and supportive policies, with the innovative drug sector leading the gains [2] - The innovative drug sector is experiencing rapid sales growth as several key products have been approved and included in medical insurance, leading to increased domestic sales [2] - Companies like BeiGene and Hutchison China MediTech have successfully commercialized their products overseas, contributing significantly to revenue growth [2]

Group 1 - Pharmaceutical stocks in Hong Kong have shown strong performance, with notable gains in companies such as 加科思-B (up 23.18%), 三叶草生物-B (up 22.09%), and others [1] - The overall performance of Hong Kong pharmaceutical companies in the first half of the year has been robust, with 恒瑞医药 achieving record high revenue and profit, and 翰森制药 exceeding revenue expectations [1] - Upcoming major conferences, including the World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO), will showcase research results from innovative domestic drugs [1] Group 2 - 海通国际 maintains a positive outlook on Hong Kong pharmaceutical companies due to their stable cash flow, rich R&D pipelines, and normalizing external licensing revenues [2] - The recent slight pullback in the Hong Kong pharmaceutical sector is attributed to rapid fund rotation, with expectations of short-term fluctuations [2] - The long-term value reassessment logic in the pharmaceutical industry remains unchanged, supported by the engineer dividend and a rich catalyst environment in the innovative drug industry [2]

Group 1 - The Hong Kong biotechnology stocks experienced a collective decline, with notable drops in several companies [1] - WuXi AppTec (02126) saw a decrease of 12.95%, closing at 4.840 [2] - BioNTech (06952) fell by 12.53%, with a latest price of 13.750 [2] Group 2 - Other companies such as Valiant (09887) and Beihai Kangcheng (01228) also reported significant declines of 9.93% and 9.75% respectively [2] - The decline extended to companies like Saint Noble (02257) and MIRXES (02629), which dropped by 9.64% and 8.43% [2] - Overall, the biotechnology sector is facing downward pressure, impacting multiple firms [1]

三叶草生物-B(02197)绩后跌超9%，截至发稿，跌9.21%，报0.69港元，成交额499.71万港元。 消息面上，8月27日，三叶草生物-B发布截至2025年6月30日止6个月中期业绩，该集团取得收入人民币 325.4万元(单位下同)，其他收入及收益1764.6万元，同比减少73.72%，经调整期内亏损9763.8万元，同 比增加11.89%；母公司拥有人应占亏损1.01亿元，同比增加6.46%；每股亏损0.08元。 公告称，尽管经营效率持续提升，但期内亏损由截至2024年6月30日止6个月的9510万元增加620万元至 截至2025年6月30日止6个月的1.01亿元，主要由于2024年确认的源于贸易应付款项部分豁免的一次性及 非经常性其他收入。 ...

消息面上，8月27日，三叶草生物-B发布截至2025年6月30日止6个月中期业绩，该集团取得收入人民币 325.4万元(单位下同)，其他收入及收益1764.6万元，同比减少73.72%，经调整期内亏损9763.8万元，同 比增加11.89%；母公司拥有人应占亏损1.01亿元，同比增加6.46%；每股亏损0.08元。 公告称，尽管经营效率持续提升，但期内亏损由截至2024年6月30日止6个月的9510万元增加620万元至 截至2025年6月30日止6个月的1.01亿元，主要由于2024年确认的源于贸易应付款项部分豁免的一次性及 非经常性其他收入。 智通财经APP获悉，三叶草生物-B(02197)绩后跌超9%，截至发稿，跌9.21%，报0.69港元，成交额 499.71万港元。 ...

Group 1 - The biotechnology sector in the Hong Kong stock market experienced a significant decline, with several companies reporting substantial drops in their stock prices [1] - Notable declines include Clover Biopharmaceuticals, which fell by 14.13%, and Beigene, which dropped by 8.33% [2] - Other companies such as Innovent Biologics and WuXi Biologics also saw declines exceeding 5%, indicating a broader trend of negative performance in the sector [1][2] Group 2 - The following companies reported specific percentage declines: Clover Biopharmaceuticals (-14.13%), Beigene (-8.33%), and Innovent Biologics (-6.50%) [2] - Additional companies with notable declines include Kintor Pharmaceutical (-6.38%), CanSino Biologics (-5.98%), and Zai Lab (-5.50%) [2] - The overall trend suggests a challenging environment for biotechnology stocks in the Hong Kong market [1]

智通财经APP讯，三叶草生物-B(02197)发布截至2025年6月30日止6个月中期业绩，该集团取得收入人民 币325.4万元(单位下同)，其他收入及收益1764.6万元，同比减少73.72%，经调整期内亏损9763.8万元， 同比增加11.89%;母公司拥有人应占亏损1.01亿元，同比增加6.46%;每股亏损0.08元。 尽管经营效率持续提升，但期内亏损由截至2024年6月30日止6个月的9510万元增加620万元至截至2025 年6月30日止6个月的1.01亿元，主要由于2024年确认的源于贸易应付款项部分豁免的一次性及非经常性 其他收入。 ...